OptiNose Inc
NASDAQ:OPTN

Watchlist Manager
OptiNose Inc Logo
OptiNose Inc
NASDAQ:OPTN
Watchlist
Price: 9.6 USD -1.13%
Market Cap: 97.2m USD

Relative Value

The Relative Value of one OPTN stock under the Base Case scenario is 26.12 USD. Compared to the current market price of 9.6 USD, OptiNose Inc is Undervalued by 63%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OPTN Relative Value
Base Case
26.12 USD
Undervaluation 63%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
71
vs Industry
70
Median 3Y
1.7
Median 5Y
2
Industry
2.7
Forward
0.9
vs History
vs Industry
Median 3Y
-3.3
Median 5Y
-2.9
Industry
21.6
Forward
-3.7
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-2.5
Industry
16.9
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-2.1
Industry
22.9
vs History
vs Industry
3
Median 3Y
-2.4
Median 5Y
-2.4
Industry
2.3
vs History
73
vs Industry
61
Median 3Y
2.1
Median 5Y
2.8
Industry
3
Forward
1.4
vs History
73
vs Industry
74
Median 3Y
2.4
Median 5Y
3.2
Industry
5.6
vs History
vs Industry
Median 3Y
-7.2
Median 5Y
-5.4
Industry
13.4
Forward
226.4
vs History
vs Industry
Median 3Y
-7.1
Median 5Y
-5.3
Industry
16.7
Forward
-13.9
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-3.1
Industry
16.1
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-3.1
Industry
18.9
vs History
73
vs Industry
24
Median 3Y
4.9
Median 5Y
5.1
Industry
2

Multiples Across Competitors

OPTN Competitors Multiples
OptiNose Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
OptiNose Inc
NASDAQ:OPTN
96.6m USD 1.2 -4.5 -8.6 -8.5
US
Eli Lilly and Co
NYSE:LLY
978B USD 16.5 53.3 35.7 38.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
528.9B USD 5.7 21.1 17.2 22.3
CH
Roche Holding AG
SIX:ROG
276.1B CHF 4.5 29.3 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
217.5B GBP 5 30.9 108.3 158.5
CH
Novartis AG
SIX:NOVN
220.2B CHF 4.9 19.1 12.1 15.6
US
Merck & Co Inc
NYSE:MRK
271.7B USD 4.2 14.3 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.5 11.5 13.3
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
145.4B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
US
OptiNose Inc
NASDAQ:OPTN
Average P/E: 24.9
Negative Multiple: -4.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.3
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
21.1
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.3
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.9
37%
0.8
CH
Novartis AG
SIX:NOVN
19.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.3
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
16.5
3%
5.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
OptiNose Inc
NASDAQ:OPTN
Average EV/EBITDA: 440
Negative Multiple: -8.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.7
34%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
17.2
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
12.1
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
1%
11.5
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
OptiNose Inc
NASDAQ:OPTN
Average EV/EBIT: 1 883.6
Negative Multiple: -8.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.2
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
22.3
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5